All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Belimumab in Lupus Nephritis

Jack Cush, MD

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
lupus_0.jpg

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

EurekAlert!

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
PSS.scleroderma.arthritis.contractures

Juvenile and Adult-onset Scleroderma Differ

Jack Cush, MD

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: Our old friend, hydroxychloroquine

Eric Dein, MD

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy
Dr. Antoni Chan synovialjoints ( View Tweet)
Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY Congratulations @LupusEurope! #EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro

Links:

David Liew drdavidliew ( View Tweet)
Different B cell depleting agents! #Eular2023 https://t.co/GsmdIHgOcl
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#Precision medicine in #SLE #Interferon is not a good predictor of remission as it takes a LONG time to normalize in #Lupus @RheumNow @eular_org #EULAR2023 abst#OP https://t.co/JkWnk94bHu
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 Please find my first article on Congress Preview of Promising New Therapies in #lupus #SLE @RheumNow https://t.co/SFvhsP8QWO https://t.co/m5UwBGCXFB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Lupus Landmark Study to Accelerate Personalized Lupus Treatments The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE. https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Our old friend, hydroxychloroquine https://t.co/NouJayD0T3 https://t.co/lRBl0UQuY3

Links:

Dr. John Cush RheumNow ( View Tweet)
Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of the etiology of Polyserositis (14 pts, 23 articles): most common - neoplasia (26.3%; Lung Lymphoma; ovarian; pancreatic), autoimmune (16.7% - SLE, AOSD) & infections (12.3%; coxackie, CMV, mTB). https://t.co/Bubd99ETgu https://t.co/VbiPB0y7pv

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included: - SLE onset age ≤ 30 (HR 1.6) - Arthritis (HR 1.6) - Organ damage (HR 2.6) - RNP+ (HR 1.7) - High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x

Links:

Dr. John Cush RheumNow ( View Tweet)
Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten has Autoimmune Disease A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals. https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×